Discounted Cash Flow (DCF) Analysis Levered

China Pharma Holdings, Inc. (CPHI)

$0.1207

+0.00 (+0.42%)
All numbers are in Millions, Currency in USD
Stock DCF: 0.01 | 0.1207 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 13.2112.3310.9210.879.648.928.267.647.076.54
Revenue (%)
Operating Cash Flow 0.841.260.61-0.04-0.250.340.320.290.270.25
Operating Cash Flow (%)
Capital Expenditure -0.14-0.05-0.14-0.87-0.44-0.27-0.25-0.23-0.22-0.20
Capital Expenditure (%)
Free Cash Flow 0.701.210.47-0.91-0.690.070.060.060.060.05

Weighted Average Cost Of Capital

Share price $ 0.1,207
Beta 0.657
Diluted Shares Outstanding 46.13
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 12,156,852.72%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.803
Total Debt 4.46
Total Equity 5.57
Total Capital 10.03
Debt Weighting 44.47
Equity Weighting 55.53
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 13.2112.3310.9210.879.648.928.267.647.076.54
Operating Cash Flow 0.841.260.61-0.04-0.250.340.320.290.270.25
Capital Expenditure -0.14-0.05-0.14-0.87-0.44-0.27-0.25-0.23-0.22-0.20
Free Cash Flow 0.701.210.47-0.91-0.690.070.060.060.060.05
WACC
PV LFCF 00000
SUM PV LFCF 0

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 5,405,850.35
Free cash flow (t + 1) 0.05
Terminal Value 0
Present Value of Terminal Value 0

Intrinsic Value

Enterprise Value 0
Net Debt -0.40
Equity Value 0.40
Shares Outstanding 46.13
Equity Value Per Share 0.01